Poor Pregnant Women with Herpes Don’t Get Meds, and Someone Notices

Fight disinformation. Get a daily recap of the facts that matter. Sign up for the free Mother Jones newsletter.


GlaxoSmithKline, in testing their herpes med, Valtrex, may have put women in harm’s way. This according to Public Citizen, which, in the Dec 1 issue of Obstetrics and Gynecology accuses the pharma giant of withholding important medication from poor and minority women.

In a recent clinical trial 168 pregnant women were given a placebo rather than an alternative herpes drug, while the other 170 were given medication. This, despite the fact that research has shown that the drug and its generic, acyclovir, reduces risks associated with herpes and pregnancy (the virus can be fatal for infants who contract the disease at birth).

The study, which took place earlier this year and was funded by GlaxoSmithKline, enrolled more than 300 black and Hispanic pregnant women at Parkland Hospital in Dallas. The hospital serves a largely indigent population. Public Citizen’s Dr. Peter Lurie is outraged:

“What I don’t understand is how you can do a research study and conclude that a drug is effective and then stare a bunch of pregnant women in the face and withhold the very drug you’ve just recommended.”

A doctor involved in the study, Dr. George Wendel, would not comment specifically on allegations that poor women were taken advantage of, instead saying that the study was designed and conducted “according to good research practices” and was approved by the hospital’s ethics review board.

ONE MORE QUICK THING:

Or at least we hope. It’s fall fundraising time, and we’re trying to raise $250,000 to help fund Mother Jones’ journalism during a shorter than normal three-week push.

If you’re reading this, a fundraising pitch at the bottom of an article, you must find our team’s reporting valuable and we hope you’ll consider supporting it with a donation of any amount right now if you can.

It’s really that simple. But if you’d like to read a bit more, our membership lead, Brian Hiatt, has a post for you highlighting some of our newsroom's impressive, impactful work of late—including two big investigations in just one day and covering voting rights the way it needs to be done—that we hope you'll agree is worth supporting.

payment methods

ONE MORE QUICK THING:

Or at least we hope. It’s fall fundraising time, and we’re trying to raise $250,000 to help fund Mother Jones’ journalism during a shorter than normal three-week push.

If you’re reading this, a fundraising pitch at the bottom of an article, you must find our team’s reporting valuable and we hope you’ll consider supporting it with a donation of any amount right now if you can.

It’s really that simple. But if you’d like to read a bit more, our membership lead, Brian Hiatt, has a post for you highlighting some of our newsroom's impressive, impactful work of late—including two big investigations in just one day and covering voting rights the way it needs to be done—that we hope you’ll agree is worth supporting.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate